• <tr id="yyy80"></tr>
  • <sup id="yyy80"></sup>
  • <tfoot id="yyy80"><noscript id="yyy80"></noscript></tfoot>
  • 99热精品在线国产_美女午夜性视频免费_国产精品国产高清国产av_av欧美777_自拍偷自拍亚洲精品老妇_亚洲熟女精品中文字幕_www日本黄色视频网_国产精品野战在线观看 ?

    Efficacy of intravitreal conbercept combined with panretinal photocoagulation for severe nonproliferative diabetic retinopathy without macular edema

    2022-04-19 06:58:30NingZhaoJianGuanNaCaiNingNingLiu

    Ning Zhao, Jian Guan, Na Cai, Ning-Ning Liu

    Department of Ophthalmology, the First Affiliated Hospital of China Medical University, Shenyang 110001, Liaoning Province, China

    Abstract

    ● KEYWORDS: conbercopt; panretinal photocoagulation;severe nonproliferative diabetic retinopathy

    INTRODUCTION

    D iabetic retinopathy is one of cause of blindness in the developed world. Preventing the recurrence and improving the prognosis of diabetic retinopathy has been the focus of research. Panretinal photocoagulation (PRP) has been the primary treatment for diabetic retinopathy. A study on the early treatment of diabetic retinopathy (ETDRS) recommended that timely PRP should be performed in patients with severe nonproliferative proliferative diabetic retinopathy (SNPDR)[1-2].However, treatment with PRP has limitations[3].

    Vascular endothelial growth factor (VEGF) plays a significant role in the neovascularization (NV) of proliferative diabetic retinopathy (PDR). Recently, anti-VEGF agents are widely used for treating PDR with satisfactory results[4-5]. Many authors have confirmed that PRP in combination with anti-VEGF agents is superior to PRP alone in protecting the visual field, reducing vitreous hemorrhage (VH), macular edema (ME), and NV regression in patients with PDR and angiogenesis[6-7].

    Conbercept (KH902; Chengdu Kanghong Biotechnology Co.,Ltd., Sichuan Province, China) is a humanized recombinant fusion protein independently developed in China that involves a VEGF binding domain of human VEGFR-1, VEGFR-2, and FC part of human immunoglobulin G1. Conbercept has a larger molecule than ranibizumab and contains the fourth binding domain of VEGFR-2. It can penetrate all retinal levels with greater binding affinity, contributing to longer clearance time[8].Recently, conbercept has been studied and used in treating diabetic ME[9], wet age-related macular degeneration[10],chronic central serous chorioretinopathy[11-12], and PDR[13-14].However, reports on the treatment of SNPDR are rare.In this study, the efficacy and safety profiles of PRP alone were evaluated with intravitreal conbercept (IVC) injection plus PRP in patients with SNPDR without ME.

    SUBJECTS AND METHODS

    Ethical ApprovalThe protocols applied were certified by the Ethics Committee of the First Affiliated Hospital of China Medical University, and in compliance with the guidelines of the Helsinki Declaration. All patients signed a written informed consent following a description of the benefits and risks before treatment. All individuals involved in the study received informed consent.

    Study DesignThis clinical research was a retrospective,comparative, and non-randomized. A total of 56 eyes were investigated from 48 patients with SNPDR and without ME who received PRP with or without conbercept pretreatment between January 2017 and December 2019. They were followed up for at least 6mo and divided into the PRP group and pulse group in the light of whether single-dose IVC was given 1wk before PRP. In the PRP group and pulse group,from January 2019 to December 2019, 23 patients (27 eyes)and 25 patients (29 eyes) are received PRP, respectively.

    ParticipantsComprehensive ophthalmic examinations,including the best-corrected visual acuity (BCVA), intraocular pressure (IOP), B-ultrasound, dilated fundus examination with slit lamp biomicroscope, 90 D non-contact slit lamp lens,color fundus photographs, spectral domain optical coherence tomography (SD-OCT; Topcon Inc., Tokyo, Japan) and fundus fluorescein angiography (FFA; TRC.50DC, Topcon, Japan)were performed in all subjects. Data were collected at baseline and 1, 3, and 6mo after treatment (named as month 1, 3, and 6,respectively).

    Criteria for inclusion into the study were the following: 1)type 2 diabetes in terms of the American Diabetes Association(ADA) or World Health Organization guidelines, age ≥18y,the glycosylated hemoglobin A1c (HbA1c) ≤10%, and blood pressure <160/90 mm Hg; 2) SNPDR absence of ME was confirmed by color fundus photographs, FFA, and OCT according to the classification criteria by ADA[15-16],central foveal thickness (CFT) was measured as the mean central macular region thickness based on the patient's fovea with a diameter of 1 mm; 3) no retinal photocoagulation or intravitreal injection of anti-VEGF was conducted before this study. Exclusion criteria were the following: 1) ME was considered when CFT was above 210 μm[15]; 2) severe keratopathy, glaucoma, lens opacity that may affect imaging,uveitis, optic neuritis, and a history of other ophthalmic disorders or intraocular surgery; 3) severe-allergic constitution,severe cardiac, hepatic, renal dysfunction, or other systemic diseases; 4) follow-up time was less than 6mo.

    Treatment Protocols A posterior segment ophthalmic surgeon(Zhao N) was responsible for both injections and PRP. After local anesthesia, patients in the PRP group underwent a scatter laser treatment using a 532-nm argon green laser (Vision one,Lumenis Inc., CA, USA) for 4 sessions in one month time with one-week intervals. For each session, photocoagulation was performed in the order of the nasal, inferior, superior,and temporal sides with 200-300 μm spot sizes and a pulse duration of 0.2s. To achieve full PRP, 300-400 spots were created for a total of 1200-1600 burns. The power of the laser was individually adjusted and ranged between 100 and 200 mW to produce yellowish-white coagulative spots. One week after IVC, patients in the pulse group underwent PRP. A topical antibiotic was instilled for 3d before treatment. Using a 29-G needle, 0.05 mL of conbercept was injected into the vitreous through the inferotemporal pars plana and 3.5-4.0 mm behind the limbus. The eye ointment, antibiotic eye drops with tobramycin and dexamethasone were used for three days. IOP was reviewed regularly.

    Study AssessmentThe difference of BCVA and CFT between the two groups was the primary outcome indicator. Secondary outcome indicators were the comparisons of visual acuity(VA) improvement, rates of treatment effectiveness, and postoperative complications.

    Criteria for treatment effectiveness: at the end of follow-up, BCVA improvement ≥2 lines or decline ≥2 lines were considered a visual improvement or visual reduction; otherwise, BCVA was considered visual stability. Treatment was effective if BCVA was increased or remained unchanged.

    Statistical AnalysisContinuous variables were presented as means with standard deviations (SDs). Categorical variables were presented as counts and proportions. Data were evaluated using one-way analysis of variance or Chi-square test using SPSS Version 22 (IBM Corp., Armonk, NY, US). SignificantPvalues were less than 0.05.

    RESULTS

    Basic CharacteristicsAs shown in Table 1, 56 eyes were contained in this study out of 48 patients with SNPDR and without ME. Data were presented as mean±SD. Ages were 50.37±5.50 and 49.41±5.60y for the PRP group and pulse group, respectively. There was no statistical difference between the groups in gender (P=0.785), age (P=0.522), duration of diabetes (P=0.172), preoperative BCVA (P=0.746), CFT(P=0.115), and IOP (P=0.116).

    Main Results

    Best-corrected visual acuityFor the PRP group, BCVA (log MAR) was 0.14±0.10 before PRP, which was deteriorated to 0.42±0.12 (P<0.001) at 1mo and to 0.28±0.11 at 3mo(P<0.001) before steadily improving to 0.18±0.15 at 6mo(P>0.05). In the pulse group, BCVA was 0.15±0.10 at baseline before PRP, which was continuously decreased at 0.25±0.11 at 1mo (P<0.001), increased subsequently to 0.18±0.09 (P<0.05)at the 3mo before improving to 0.09±0.08 at 6mo (P<0.001).In the period of follow-up, the BCVA in the pulse group was better than that in the PRP group, especially at 1 and 3mo(0.42±0.12vs0.25±0.11,P<0.001; 0.28±0.11vs0.18±0.09,P<0.001; and 0.18±0.15vs0.09±0.08,P=0.008, respectively;Table 2).

    Center foveal thicknessThe baseline CFT was 188.74±4.38 in the PRP group and 187.07±3.40 μm in the pulse group(P=0.115). In the PRP group, the thickness of CFT after PRP peaked at 277.30±13.74 μm at 1mo, then decreased from 223.59±8.35 to 210.00±8.51 μm between 3 and 6mo(P<0.001). In the pulse group, the CFT briefly increased to 221.17±6.40 μm at 1mo, which was significant compared to the baseline (P<0.001), then steadily decreased to 185.14±4.61 at 3mo and to 187.07±3.29 μm at 6mo. The changes at 3 and 6mo from the baseline were not statistically significant(P>0.05,P=0.073,P=0.077, respectively), suggesting that CFT returned to its initial foveal thickness. During the followup, the mean CFT of the pulse group was significantly lower than that of the PRP group (277.30±13.74vs221.17±6.40,t=19.412; 223.59±8.35vs185.14±4.61,t=20.815; 210.00±8.51vs187.07±3.29 μm,t=13.471, allP<0.001; Table 3).

    The Secondary Outcome

    Visual acuity improvement and rates of treatmenteffectivenessVA improvement following treatment is presented in Table 4. In the PRP group, VA was increased in 3 patients (11.11%), decreased in 5 patients (18.52%), unchanged in 19 patients (70.37%) at 6mo. In the pulse group, VA was improved in 13 patients (44.83%), unchanged in 16 out of 29 eyes (55.17%) with no patients having decreased VA. The rate of effectiveness in VA in the pulse group was higher than that in the PRP group (81.48%vs100%,χ2=7.09,P<0.05).

    Postoperative complications and adverse eventsThroughout the period of follow-up, no evident eye complications, or systemic adverse reactions (e.g., uveitis reaction, rapid aggravation of cataract, neovascular glaucoma, endophthalmitis, and retinal detachment) were identified. In the pulse group, 2 cases (6.9%)of subconjunctival hemorrhage and one case of transiently increased IOP were reported, the cases were mild and the patients recovered without treatment. At 6mo follow-up, mild recurrent VH with visible fundus information occurred in 5 eyes (18.52%) in the PRP group; it was difficult to assess the retina nerve fiber layer or small vessels[17]. Patients were instructed to monitor the patient's blood glucose, blood pressure and other systemic conditions and take Chinese medicine orally (hexuemingmu). The VH was completely absorbed after 2wk.

    Table 1 The comparison of basic characteristics between PRP and pulse group mean±SD

    Table 2 BCVA between the two groups before and after treatment mean±SD

    Table 3 CFT between the two groups before and after treatment mean±SD, μm

    Table 4 logMAR BCVA improvement between the two groups n (%)

    DISCUSSION

    The clinical effect of IVC combined with PRP and PRP alone in patients with SNPDR and absence of ME was first compared in this study. The findings show that in most patients, both treatment regimens preserved good VA. However, by reducing PRP-induced ME, the combination therapy was more successful and rapid; BCVA was improved by combination therapy than PRP alone.

    To reduce the frequency of visual loss and avoid subsequent NV, PRP should be conducted in patients with severe nonproliferative or early PDR, according to the recommendations of the ETDRS[18]. However, studies have shown that PRP decreased moderate VA in the treatment group by 25%-43%,causing ME, which is the most common cause of VA decline in diabetic eyes[19]. Therefore, the implementation of PRP is hesitated by diabetic patients with SNPDR or nonhigh risk PDR, especially those with good vision. In our study, 81.48%of patients' demonstrated stable or improved VA, 18.52% had decreased VA in the PRP group with no significant difference in VA between baseline and 6mo after PRP. Ganekalet al[20],Shimuraet al[21], McDonald and Schatz[22]reported that stable and improved vision rates were 81.58% and 85%, respectively,in patients with PDR, and no clinically significant ME, whereas 18.42% or 15% of patients had decreased vision after PRP,similar to our results. Compared with other studies, the clinical significance of ME may be caused by pre-existing ME and uncontrolled systemic conditions before and after PRP, leading to decreased vision after PRP[19,22]. In this study, all participants received appropriate treatment for their general diabetes and hypertension status, accompanied by well-controlled HbA1c level and blood pressure during follow-up.

    In this study, the changes of CFT were increased in the PRP group at 1mo after PRP before was slowly decreased. CFT at 6mo of follow-up was still higher than that at baseline but did not exceed the range of 368-572 μm for clinical significance of ME[20]. However, VA was decreased significantly after 1 and 3mo of PRP. With follow-up time, VA was steadily improved,reaching the baseline level at the end of follow-up. Therefore,according to the findings of Diabetic Retinopathy Clinical Research Network[23], the thickness of fovea in OCT is not correlated with VA. The measurement of fovea thickness may not be a practical guide for VA. This was also consistent with the findings of Leeet al[15]that VA in patients with severe diabetic retinopathy without ME has not affected by mild macular thickening persists and PRP. It was noteworthy that laser photocoagulation in this study was not conducted in the macular region. The increase in macular thickening was triggered by PRP damage to the perimacular tissue. The heat conduction of retinal photocoagulation from retinal pigment epithelium reaches the retina, causing focal inflammation and likely contributing to ME[24-27]. To further strengthen the therapeutic effect of PRP and solve the issue of rapid vision loss and VH after PRP, the combination of intravitreal injection of anti-VEGF drugs and laser photocoagulation has been proposed by many researchers[28-31]. In this study, we used the characteristics of conbercept of lower VEGF dissociation rate, higher binding affinity, decreased extracellular matrix adhesion, and a longer clearance time to combine with PRP to observe its safety and effectiveness. Our data confirmed that conbercept reduced PRP-induced ME and prevented PRPinduced visual dysfunction. In the pulse group, combined treatment increased BCVA, resulting in more significant vision gain than in the PRP group; the 100% rate of effectiveness in VA was also higher than that in the PRP group (81.48%).

    These findings suggest that the combined therapy was superior to PRP alone in improving VA and CFT, and the increase in VA and decrease in CFT were significant after 1mo with one dose of IVC. More importantly, improving vision within a short time frame increases patients' satisfaction, the treatment confidence, and boosts the cure rate.

    IVC may play a synergistic role with PRP in reducing angiogenesis, leakage, restoring retinal transparency, decreasing the need for high laser energy and effectively reducing ME,which might explain the results. In this study, IVC before PRP did not prevent the transient increase in CFT 1mo after PRP. Shimuraet al[21]considered that to inhibit the damage caused by additional photocoagulation, a one-week interval of PRP treatment was inadequate to recover from the macular damage and retinal injury of 500 burns. Their results showed that biweekly treatments could restore macular thickening more quickly after PRP than weekly treatment. However,changes in the progression of retinopathy might increase over a more extended period of treatment. Perhaps, IVC combined biweekly PRP is a new alternative in the future.

    The small sample size and short follow-up period were the limitations of our study. It is necessary to implement further researches with larger sample size and longer follow-up, for example, more than 12-month, in the future. Meanwhile, visual function after treatment was not evaluated for both groups.Furthermore, there was a lack of automated quantitative approaches for assessing hard exudate and the amount of microaneurysms,which are closely linked to the progression of diabetic retinopathy.

    In conclusion,for patients with SNPDR without ME, PRP alone and IVC combined with PRP treatment could maintain good VA. However, IVC seems to be a promising adjunctive therapy for PRP, and the combination therapy may increase BCVA and prevent visual loss and ME caused by PRP.

    ACKNOWLEDGEMENTS

    We thank all participants in this study. Thanks to the assistance of Dr. Han JN, Zhao Y and other doctors, the ophthalmology examination was completed.

    Conflicts of Interest: Zhao N,None;Guan J,None;Cai N,None;Liu NN,None.

    亚洲欧洲国产日韩| 在线av久久热| 国产xxxxx性猛交| 国产欧美日韩一区二区三区在线| 精品亚洲乱码少妇综合久久| 国产在线观看jvid| 少妇人妻 视频| 在线亚洲精品国产二区图片欧美| 中文字幕人妻熟女乱码| 每晚都被弄得嗷嗷叫到高潮| 我的亚洲天堂| 午夜av观看不卡| 久久亚洲国产成人精品v| 亚洲男人天堂网一区| 美女中出高潮动态图| 我要看黄色一级片免费的| 欧美成狂野欧美在线观看| 水蜜桃什么品种好| 两人在一起打扑克的视频| 天天添夜夜摸| 最近最新中文字幕大全免费视频 | 成在线人永久免费视频| 欧美成人精品欧美一级黄| 美女主播在线视频| 国产爽快片一区二区三区| 视频区图区小说| 亚洲中文字幕日韩| 一本—道久久a久久精品蜜桃钙片| 成人免费观看视频高清| 日韩一区二区三区影片| av电影中文网址| 色播在线永久视频| 国产精品 欧美亚洲| 1024视频免费在线观看| 亚洲精品美女久久久久99蜜臀 | 视频区欧美日本亚洲| 蜜桃在线观看..| 老司机在亚洲福利影院| 99久久99久久久精品蜜桃| 国产片内射在线| 99精品久久久久人妻精品| 国产免费福利视频在线观看| 久久亚洲精品不卡| 天堂俺去俺来也www色官网| 色视频在线一区二区三区| 性少妇av在线| 五月开心婷婷网| 精品国产乱码久久久久久男人| 精品免费久久久久久久清纯 | 少妇精品久久久久久久| 一级黄色大片毛片| 精品一区二区三区av网在线观看 | 国产高清videossex| 波多野结衣一区麻豆| 亚洲国产精品一区二区三区在线| 国产一区二区三区综合在线观看| 一区福利在线观看| 精品福利观看| 久久 成人 亚洲| 大片电影免费在线观看免费| 69精品国产乱码久久久| 亚洲国产欧美一区二区综合| 老司机靠b影院| av国产久精品久网站免费入址| 成年女人毛片免费观看观看9 | 妹子高潮喷水视频| 亚洲国产欧美网| 欧美精品av麻豆av| 精品熟女少妇八av免费久了| 亚洲一区二区三区欧美精品| 中文字幕人妻丝袜制服| 一二三四社区在线视频社区8| 欧美精品一区二区大全| 97人妻天天添夜夜摸| 老司机亚洲免费影院| 国产片特级美女逼逼视频| 一边摸一边做爽爽视频免费| 天天躁夜夜躁狠狠躁躁| 天天躁狠狠躁夜夜躁狠狠躁| 免费少妇av软件| 亚洲第一青青草原| 中文字幕人妻丝袜制服| 亚洲五月婷婷丁香| 极品人妻少妇av视频| 国产精品欧美亚洲77777| 啦啦啦在线免费观看视频4| 老司机影院成人| 热re99久久精品国产66热6| 一个人免费看片子| 九草在线视频观看| 亚洲精品自拍成人| 可以免费在线观看a视频的电影网站| 黄色怎么调成土黄色| 最近手机中文字幕大全| 飞空精品影院首页| 国产精品麻豆人妻色哟哟久久| 国产亚洲精品久久久久5区| 中文字幕色久视频| 久久久久网色| 日韩欧美一区视频在线观看| 国产亚洲精品久久久久5区| 大片电影免费在线观看免费| 婷婷色av中文字幕| 天堂中文最新版在线下载| 91麻豆av在线| 999精品在线视频| 黄色视频不卡| 大片电影免费在线观看免费| 999精品在线视频| 国产欧美日韩精品亚洲av| 国产成人精品久久久久久| 国产福利在线免费观看视频| 97精品久久久久久久久久精品| 欧美亚洲日本最大视频资源| 亚洲图色成人| 日韩 欧美 亚洲 中文字幕| 99国产精品免费福利视频| 天堂中文最新版在线下载| 亚洲美女黄色视频免费看| 一级片'在线观看视频| 日日夜夜操网爽| 一二三四在线观看免费中文在| 日韩制服丝袜自拍偷拍| 亚洲人成网站在线观看播放| 中文字幕人妻丝袜制服| 日韩伦理黄色片| 欧美少妇被猛烈插入视频| 天天躁日日躁夜夜躁夜夜| 少妇粗大呻吟视频| 国产精品久久久人人做人人爽| 国产高清不卡午夜福利| 亚洲天堂av无毛| 国产99久久九九免费精品| 国产精品一二三区在线看| 精品一区二区三卡| 亚洲成色77777| 欧美亚洲 丝袜 人妻 在线| 丰满人妻熟妇乱又伦精品不卡| 国产视频一区二区在线看| 久久精品国产亚洲av涩爱| 日本一区二区免费在线视频| 少妇 在线观看| 国产一区二区三区综合在线观看| 一边亲一边摸免费视频| 飞空精品影院首页| 亚洲一码二码三码区别大吗| 婷婷丁香在线五月| 最近手机中文字幕大全| 人人妻,人人澡人人爽秒播 | 精品久久蜜臀av无| 亚洲三区欧美一区| 夫妻性生交免费视频一级片| 精品一区在线观看国产| 久久精品国产a三级三级三级| 黄频高清免费视频| 欧美日韩视频高清一区二区三区二| 男人舔女人的私密视频| 老鸭窝网址在线观看| 久久久久久久精品精品| 久久国产精品男人的天堂亚洲| 久久久亚洲精品成人影院| 脱女人内裤的视频| av视频免费观看在线观看| 婷婷色综合大香蕉| 国产精品免费视频内射| 国产熟女欧美一区二区| 亚洲情色 制服丝袜| 久久人人97超碰香蕉20202| 肉色欧美久久久久久久蜜桃| 亚洲 欧美一区二区三区| 久久久国产欧美日韩av| 两性夫妻黄色片| 丝袜美足系列| 亚洲,欧美,日韩| 亚洲av男天堂| 亚洲精品中文字幕在线视频| 国产福利在线免费观看视频| 美女福利国产在线| 亚洲成人国产一区在线观看 | 久久人人爽人人片av| 亚洲精品久久成人aⅴ小说| 国产av精品麻豆| 亚洲熟女精品中文字幕| 久久午夜综合久久蜜桃| 九色亚洲精品在线播放| 男女无遮挡免费网站观看| 国产免费福利视频在线观看| 久久久久久亚洲精品国产蜜桃av| 国产成人a∨麻豆精品| 国产一级毛片在线| 尾随美女入室| 久久精品成人免费网站| 高清av免费在线| 不卡av一区二区三区| 一个人免费看片子| 国产免费福利视频在线观看| 亚洲精品乱久久久久久| 好男人视频免费观看在线| 自线自在国产av| 国产男女超爽视频在线观看| 女人精品久久久久毛片| videosex国产| 久久这里只有精品19| 亚洲一区中文字幕在线| 成人亚洲欧美一区二区av| 欧美另类一区| 免费少妇av软件| 波多野结衣一区麻豆| 国产精品熟女久久久久浪| 男女床上黄色一级片免费看| 国产亚洲欧美精品永久| 国产日韩欧美亚洲二区| 制服诱惑二区| 一级黄片播放器| 丝袜美腿诱惑在线| 免费在线观看日本一区| 国产成人系列免费观看| 亚洲av成人精品一二三区| 狂野欧美激情性bbbbbb| 叶爱在线成人免费视频播放| 免费在线观看日本一区| 在线观看免费视频网站a站| 女警被强在线播放| 亚洲熟女毛片儿| 免费观看人在逋| 日本av手机在线免费观看| 国产免费又黄又爽又色| 国产成人91sexporn| a 毛片基地| 亚洲中文av在线| 可以免费在线观看a视频的电影网站| 一二三四在线观看免费中文在| 免费高清在线观看日韩| xxxhd国产人妻xxx| 国产欧美日韩一区二区三 | 成年女人毛片免费观看观看9 | 久久精品亚洲av国产电影网| 亚洲欧美精品综合一区二区三区| 亚洲七黄色美女视频| 亚洲精品久久午夜乱码| 亚洲,欧美精品.| 亚洲免费av在线视频| 国产亚洲一区二区精品| 亚洲av欧美aⅴ国产| 亚洲国产欧美网| 免费在线观看完整版高清| 日韩大片免费观看网站| 狠狠精品人妻久久久久久综合| 男的添女的下面高潮视频| 啦啦啦在线免费观看视频4| av视频免费观看在线观看| 亚洲欧洲国产日韩| netflix在线观看网站| 少妇精品久久久久久久| 69精品国产乱码久久久| 一区二区三区激情视频| 交换朋友夫妻互换小说| 99九九在线精品视频| 亚洲,欧美,日韩| 免费久久久久久久精品成人欧美视频| 国产成人系列免费观看| 亚洲免费av在线视频| 飞空精品影院首页| 国产色视频综合| 曰老女人黄片| 久久精品国产亚洲av高清一级| 真人做人爱边吃奶动态| 中文字幕人妻丝袜一区二区| 亚洲一卡2卡3卡4卡5卡精品中文| 99久久综合免费| 精品一区二区三卡| 最新在线观看一区二区三区 | 色精品久久人妻99蜜桃| 一本久久精品| 亚洲欧美色中文字幕在线| 久久久亚洲精品成人影院| 一本久久精品| 欧美日韩综合久久久久久| 久久人人爽av亚洲精品天堂| 精品人妻在线不人妻| 日韩伦理黄色片| 黄网站色视频无遮挡免费观看| 精品免费久久久久久久清纯 | a级毛片在线看网站| 婷婷色综合www| 看十八女毛片水多多多| 黄色毛片三级朝国网站| 在线天堂中文资源库| 精品一区在线观看国产| 韩国精品一区二区三区| 狠狠婷婷综合久久久久久88av| 各种免费的搞黄视频| 亚洲国产最新在线播放| 男女午夜视频在线观看| 香蕉丝袜av| 亚洲综合色网址| 秋霞在线观看毛片| 欧美日本中文国产一区发布| 少妇人妻久久综合中文| 久久久久网色| 国产成人系列免费观看| 97人妻天天添夜夜摸| 精品一品国产午夜福利视频| 高清黄色对白视频在线免费看| 大片电影免费在线观看免费| 97人妻天天添夜夜摸| 另类亚洲欧美激情| 日本色播在线视频| 国产成人a∨麻豆精品| 老熟女久久久| 成年美女黄网站色视频大全免费| 日本猛色少妇xxxxx猛交久久| 妹子高潮喷水视频| 亚洲成色77777| 多毛熟女@视频| 久久久久久人人人人人| 少妇裸体淫交视频免费看高清 | 亚洲色图 男人天堂 中文字幕| 久热这里只有精品99| 青草久久国产| 亚洲av片天天在线观看| 国产精品香港三级国产av潘金莲 | 老汉色∧v一级毛片| 成年美女黄网站色视频大全免费| 国产一区二区 视频在线| 精品福利观看| 国产精品.久久久| 成人18禁高潮啪啪吃奶动态图| 自线自在国产av| av有码第一页| 99久久精品国产亚洲精品| 五月天丁香电影| 国产一区二区三区综合在线观看| 中文字幕人妻熟女乱码| 不卡av一区二区三区| 亚洲第一青青草原| 性少妇av在线| 中文乱码字字幕精品一区二区三区| kizo精华| 老司机午夜十八禁免费视频| 国产精品一区二区精品视频观看| 国产欧美日韩精品亚洲av| 可以免费在线观看a视频的电影网站| 黄网站色视频无遮挡免费观看| 性少妇av在线| 欧美精品亚洲一区二区| 国产一区二区激情短视频 | 一区二区av电影网| 久久久久久久国产电影| 久久精品久久久久久噜噜老黄| 午夜视频精品福利| 国产成人一区二区三区免费视频网站 | 美女视频免费永久观看网站| 婷婷色综合大香蕉| 自线自在国产av| 国产成人av教育| 热re99久久精品国产66热6| 欧美日本中文国产一区发布| 成人国产av品久久久| 这个男人来自地球电影免费观看| 午夜91福利影院| 久久久欧美国产精品| 婷婷色综合大香蕉| 免费在线观看视频国产中文字幕亚洲 | 国产无遮挡羞羞视频在线观看| 99精国产麻豆久久婷婷| 中文字幕最新亚洲高清| 午夜免费成人在线视频| 国产精品久久久久久人妻精品电影 | 国产又爽黄色视频| 中文字幕人妻熟女乱码| 曰老女人黄片| 午夜福利在线免费观看网站| 国产人伦9x9x在线观看| 日本五十路高清| 免费看十八禁软件| 欧美人与性动交α欧美软件| 深夜精品福利| 一本—道久久a久久精品蜜桃钙片| 老汉色∧v一级毛片| 人人妻人人澡人人爽人人夜夜| 国产成人91sexporn| 一边摸一边做爽爽视频免费| 亚洲成色77777| 在线观看国产h片| 午夜福利视频在线观看免费| 大香蕉久久成人网| 亚洲中文日韩欧美视频| 在线观看免费视频网站a站| 国产成人一区二区三区免费视频网站 | 狂野欧美激情性bbbbbb| 最近中文字幕2019免费版| www.精华液| 嫩草影视91久久| 国产色视频综合| 亚洲国产精品成人久久小说| 久久精品人人爽人人爽视色| av一本久久久久| tube8黄色片| 最新的欧美精品一区二区| 一级a爱视频在线免费观看| 母亲3免费完整高清在线观看| 久久久久国产精品人妻一区二区| 国产男女超爽视频在线观看| 国产成人a∨麻豆精品| 亚洲人成网站在线观看播放| 国产成人一区二区三区免费视频网站 | 18禁国产床啪视频网站| 久久青草综合色| 看十八女毛片水多多多| 欧美人与性动交α欧美软件| 日韩人妻精品一区2区三区| 精品少妇一区二区三区视频日本电影| 亚洲熟女精品中文字幕| 精品国产超薄肉色丝袜足j| 久久精品国产亚洲av高清一级| 欧美乱码精品一区二区三区| 天堂中文最新版在线下载| 曰老女人黄片| 成人手机av| 中文字幕制服av| 黄色片一级片一级黄色片| 国产日韩欧美亚洲二区| 免费久久久久久久精品成人欧美视频| 尾随美女入室| 国产精品免费大片| 97在线人人人人妻| 中文欧美无线码| 777久久人妻少妇嫩草av网站| a级毛片在线看网站| 建设人人有责人人尽责人人享有的| 久9热在线精品视频| 黑人巨大精品欧美一区二区蜜桃| 日韩大片免费观看网站| 两个人免费观看高清视频| 成人影院久久| av有码第一页| av不卡在线播放| 免费观看av网站的网址| 日日摸夜夜添夜夜爱| 一本一本久久a久久精品综合妖精| 日本猛色少妇xxxxx猛交久久| 一区二区日韩欧美中文字幕| 久久久久久久精品精品| 99国产综合亚洲精品| 中文乱码字字幕精品一区二区三区| 亚洲精品日韩在线中文字幕| 亚洲精品国产av蜜桃| 日韩大片免费观看网站| 另类亚洲欧美激情| 亚洲精品av麻豆狂野| 欧美日韩亚洲综合一区二区三区_| 日本欧美国产在线视频| 欧美日韩成人在线一区二区| 日韩制服丝袜自拍偷拍| 大片电影免费在线观看免费| 中文字幕人妻丝袜一区二区| 亚洲精品第二区| 国产色视频综合| 亚洲图色成人| 日本猛色少妇xxxxx猛交久久| 久久av网站| 99国产精品99久久久久| 久久99一区二区三区| 午夜激情av网站| 后天国语完整版免费观看| 天天躁夜夜躁狠狠躁躁| 又粗又硬又长又爽又黄的视频| 亚洲成人国产一区在线观看 | 亚洲七黄色美女视频| 秋霞在线观看毛片| 人人妻人人澡人人看| 搡老岳熟女国产| 国产精品一区二区在线不卡| 90打野战视频偷拍视频| 曰老女人黄片| 国产成人精品久久久久久| 欧美国产精品va在线观看不卡| 99国产综合亚洲精品| 777久久人妻少妇嫩草av网站| 亚洲熟女精品中文字幕| av在线老鸭窝| 久久影院123| 视频区欧美日本亚洲| 亚洲精品日本国产第一区| 免费高清在线观看视频在线观看| 国产在线一区二区三区精| 中文精品一卡2卡3卡4更新| 国产午夜精品一二区理论片| 久久99热这里只频精品6学生| 女性生殖器流出的白浆| 99久久综合免费| 天天添夜夜摸| 在线天堂中文资源库| 国产精品秋霞免费鲁丝片| 欧美成人精品欧美一级黄| 欧美在线一区亚洲| 一区二区三区乱码不卡18| 精品人妻在线不人妻| 青春草亚洲视频在线观看| 欧美激情 高清一区二区三区| 欧美中文综合在线视频| 青春草视频在线免费观看| 十分钟在线观看高清视频www| av天堂在线播放| 国产成人免费观看mmmm| 好男人电影高清在线观看| 欧美日韩一级在线毛片| 亚洲精品在线美女| 欧美亚洲 丝袜 人妻 在线| 久久久精品区二区三区| 久久精品亚洲av国产电影网| 建设人人有责人人尽责人人享有的| 51午夜福利影视在线观看| 天天躁日日躁夜夜躁夜夜| 人人妻人人爽人人添夜夜欢视频| 老汉色∧v一级毛片| 又黄又粗又硬又大视频| 日本wwww免费看| 国产国语露脸激情在线看| 成人亚洲欧美一区二区av| 国产一区二区在线观看av| 久久久久网色| 久久精品国产亚洲av涩爱| 亚洲精品国产一区二区精华液| 亚洲欧美日韩另类电影网站| 狠狠婷婷综合久久久久久88av| 一级毛片电影观看| 成人国产一区最新在线观看 | 高清av免费在线| 亚洲五月色婷婷综合| 性色av乱码一区二区三区2| 国产成人免费无遮挡视频| 国产精品二区激情视频| 欧美人与性动交α欧美精品济南到| 色播在线永久视频| 晚上一个人看的免费电影| 亚洲成色77777| 国产男人的电影天堂91| 国产成人一区二区在线| 精品少妇内射三级| 电影成人av| 老汉色∧v一级毛片| 91麻豆av在线| 波多野结衣av一区二区av| 别揉我奶头~嗯~啊~动态视频 | 午夜免费鲁丝| 巨乳人妻的诱惑在线观看| 在线观看免费午夜福利视频| 亚洲欧美精品综合一区二区三区| 女性生殖器流出的白浆| 真人做人爱边吃奶动态| 午夜福利在线免费观看网站| 亚洲欧美一区二区三区久久| 最近中文字幕2019免费版| 男男h啪啪无遮挡| 午夜福利在线免费观看网站| 99久久综合免费| 美女脱内裤让男人舔精品视频| 最近手机中文字幕大全| 性色av乱码一区二区三区2| 欧美精品啪啪一区二区三区 | 国产深夜福利视频在线观看| bbb黄色大片| 欧美精品高潮呻吟av久久| 国产精品亚洲av一区麻豆| 精品亚洲乱码少妇综合久久| 国产一区二区在线观看av| 美女国产高潮福利片在线看| 久久av网站| 亚洲熟女精品中文字幕| 免费在线观看视频国产中文字幕亚洲 | 亚洲精品久久午夜乱码| 999久久久国产精品视频| 久久人妻福利社区极品人妻图片 | 激情视频va一区二区三区| 国产黄色免费在线视频| 亚洲精品一区蜜桃| 久久久精品94久久精品| 亚洲av电影在线进入| 久久久久国产精品人妻一区二区| 一区二区av电影网| 久久亚洲精品不卡| 精品高清国产在线一区| 中国美女看黄片| av天堂在线播放| 国产精品一区二区在线不卡| 丝袜美腿诱惑在线| 一区二区三区激情视频| 爱豆传媒免费全集在线观看| 午夜福利,免费看| 超碰成人久久| 久9热在线精品视频| 美女大奶头黄色视频| 韩国精品一区二区三区| 欧美久久黑人一区二区| 国产精品.久久久| 一级黄色大片毛片| 亚洲精品乱久久久久久| 岛国毛片在线播放| 国产精品免费视频内射| 首页视频小说图片口味搜索 | 91精品伊人久久大香线蕉| a级毛片在线看网站| 精品亚洲成国产av| 高潮久久久久久久久久久不卡| 亚洲七黄色美女视频| 在线亚洲精品国产二区图片欧美| 多毛熟女@视频| 久久国产精品大桥未久av| 久久久精品区二区三区| 大码成人一级视频| 国产成人免费无遮挡视频| 久热这里只有精品99| 亚洲av电影在线观看一区二区三区|